Intervacc AB (publ) (STO:IVACC)

Market Cap	405.57M
Revenue (ttm)	11.79M
Net Income (ttm)	-75.52M
Shares Out	340.81M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,379,293
Average Volume	921,926
Open	1.262
Previous Close	1.270
Day's Range	1.140 - 1.300
52-Week Range	0.751 - 4.795
Beta	0.64
RSI	73.50
Earnings Date	May 14, 2025

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses which is in commercial stage; INV274, antigens for a vaccine against Strep. suis infectionfor the treatment of weaned piglets which is in development stage; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows which is in development stage. It also engages in marketing and distribution of veterinary products in the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 15
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IVACC

Financial Performance

In 2024, Intervacc AB's revenue was 11.79 million, an increase of 46.84% compared to the previous year's 8.03 million. Losses were -75.52 million, -26.58% less than in 2023.